CL2021003409A1 - Agonistas de receptor de melanocortina-4 - Google Patents

Agonistas de receptor de melanocortina-4

Info

Publication number
CL2021003409A1
CL2021003409A1 CL2021003409A CL2021003409A CL2021003409A1 CL 2021003409 A1 CL2021003409 A1 CL 2021003409A1 CL 2021003409 A CL2021003409 A CL 2021003409A CL 2021003409 A CL2021003409 A CL 2021003409A CL 2021003409 A1 CL2021003409 A1 CL 2021003409A1
Authority
CL
Chile
Prior art keywords
compound
present
melanocortin
receptor agonists
activity against
Prior art date
Application number
CL2021003409A
Other languages
English (en)
Inventor
Seung Wan Kang
Hee Dong Park
Su Jin Yeo
Hyun Seo Park
Ji Ho Hong
Hye Won Ahn
Eun Sil Choi
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2021003409A1 publication Critical patent/CL2021003409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona a un compuesto que exhibe excelente actividad agonista contra los receptores de melanocortina. Más específicamente, la presente invención se relaciona a un compuesto de la Fórmula 1, una composición farmacéutica que comprende el compuesto como un ingrediente activo, y un uso del mismo, y el compuesto de la presente invención exhibe excelente actividad agonista contra los receptores de melacortina-4 y puede ser particularmente útil en prevenir o tratar obesidad, diabetes, inflamación y disfunción eréctil.
CL2021003409A 2019-11-07 2021-12-17 Agonistas de receptor de melanocortina-4 CL2021003409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190141649 2019-11-07

Publications (1)

Publication Number Publication Date
CL2021003409A1 true CL2021003409A1 (es) 2022-08-19

Family

ID=75848091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003409A CL2021003409A1 (es) 2019-11-07 2021-12-17 Agonistas de receptor de melanocortina-4

Country Status (25)

Country Link
US (1) US20220289731A1 (es)
EP (1) EP3953327B1 (es)
JP (2) JP7467510B2 (es)
KR (1) KR102485182B1 (es)
CN (1) CN113939500A (es)
AU (1) AU2020377805B2 (es)
BR (1) BR112021022497A2 (es)
CA (1) CA3135543C (es)
CL (1) CL2021003409A1 (es)
CO (1) CO2021017401A2 (es)
DK (1) DK3953327T3 (es)
ES (1) ES2970510T3 (es)
FI (1) FI3953327T3 (es)
HU (1) HUE064968T2 (es)
IL (1) IL288921A (es)
MX (1) MX2021014074A (es)
PE (1) PE20220766A1 (es)
PL (1) PL3953327T3 (es)
PT (1) PT3953327T (es)
SG (1) SG11202112163XA (es)
SI (1) SI3953327T1 (es)
TW (1) TWI754448B (es)
UA (1) UA127255C2 (es)
WO (1) WO2021091283A1 (es)
ZA (1) ZA202110474B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240366A1 (es) * 2020-10-29 2024-03-04 Lg Chemical Ltd Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma
PE20240367A1 (es) * 2020-10-29 2024-03-04 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma
WO2022092908A1 (ko) * 2020-10-29 2022-05-05 주식회사 엘지화학 무정형의 멜라노코르틴-4 수용체 작용제
JP2023548327A (ja) * 2020-10-29 2023-11-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
EP4219473A4 (en) * 2020-10-29 2024-03-13 Lg Chem, Ltd. CRYSTAL TYPE II OF A MALANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
JP2024501829A (ja) * 2020-12-22 2024-01-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法
AU2021409684A1 (en) * 2020-12-22 2023-07-06 Lg Chem, Ltd. Use as selective agonist of malanocortin-4 receptor
US20240051944A1 (en) * 2020-12-22 2024-02-15 Lg Chem, Ltd. Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor
WO2022139441A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법
KR20220090456A (ko) * 2020-12-22 2022-06-29 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 i 및 이의 제조방법
US20240148743A1 (en) * 2021-01-21 2024-05-09 Lg Chem, Ltd. Uses of melanocortin-4 receptor agonist
US20240190856A1 (en) * 2021-02-26 2024-06-13 Lg Chem, Ltd. Melanocortin-4 receptor agonist
EP4317150A1 (en) * 2021-05-06 2024-02-07 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
MX2023013044A (es) * 2021-05-06 2023-11-15 Lg Chemical Ltd Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
CN117242063A (zh) * 2021-05-07 2023-12-15 株式会社Lg化学 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法
AU2022269992A1 (en) * 2021-05-07 2023-11-02 Lg Chem, Ltd. Sulfate crystals of melanocortin receptor agonist compound and method of producing same
CA3217468A1 (en) * 2021-05-07 2022-11-10 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
TWI838114B (zh) * 2022-02-08 2024-04-01 南韓商Ｌｇ化學股份有限公司 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途
TW202345798A (zh) * 2022-03-28 2023-12-01 南韓商Ｌｇ化學股份有限公司 預防或治療肥胖的聯合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4929601A (en) * 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DE60219295T2 (de) * 2001-02-28 2008-01-03 Merck & Co., Inc. Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
KR100661118B1 (ko) * 2003-11-12 2006-12-26 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
DK3150578T3 (da) * 2014-05-29 2021-01-18 Mitsubishi Tanabe Pharma Corp Ny pyrrolidinforbindelse og anvendelse som melanocortin-receptoragonist
PE20240367A1 (es) * 2020-10-29 2024-03-04 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma

Also Published As

Publication number Publication date
WO2021091283A1 (en) 2021-05-14
ZA202110474B (en) 2023-09-27
KR102485182B1 (ko) 2023-01-06
ES2970510T3 (es) 2024-05-29
UA127255C2 (uk) 2023-06-21
BR112021022497A2 (pt) 2022-05-17
MX2021014074A (es) 2021-12-10
JP2022548452A (ja) 2022-11-21
FI3953327T3 (fi) 2024-01-31
CA3135543A1 (en) 2021-05-14
DK3953327T3 (da) 2024-02-05
TW202128681A (zh) 2021-08-01
SI3953327T1 (sl) 2024-04-30
EP3953327A4 (en) 2022-06-29
CN113939500A (zh) 2022-01-14
SG11202112163XA (en) 2021-12-30
AU2020377805A1 (en) 2021-11-25
PE20220766A1 (es) 2022-05-16
PL3953327T3 (pl) 2024-05-06
EP3953327A1 (en) 2022-02-16
CA3135543C (en) 2023-08-01
JP2024028542A (ja) 2024-03-04
CO2021017401A2 (es) 2022-04-08
IL288921A (en) 2022-02-01
AU2020377805B2 (en) 2023-02-02
PT3953327T (pt) 2024-02-05
TWI754448B (zh) 2022-02-01
EP3953327B1 (en) 2023-12-27
JP7467510B2 (ja) 2024-04-15
KR20210055624A (ko) 2021-05-17
US20220289731A1 (en) 2022-09-15
HUE064968T2 (hu) 2024-04-28

Similar Documents

Publication Publication Date Title
CL2021003409A1 (es) Agonistas de receptor de melanocortina-4
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
CL2013003547A1 (es) Peptido derivado de oxintomodulina; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; uso del peptido para tratar la obesidad.
UY32238A (es) Agonistas de los receptores de la melanocortina
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2020009390A (es) Suministro transdermico y/o dermico de agentes activos lipofilicos.
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CL2023003794A1 (es) Agonista del receptor de glp-1 y composición y uso del mismo
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CL2015003286A1 (es) (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos
CL2009000660A1 (es) Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
ECSP19044591A (es) Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
UA130656U (uk) Композиція з протитуберкульозною дією